Skip to main content
    G

    Globus Medical (GMED)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $70.51
    -1.63 (-2.26%)

    Market Cap: $9.57B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Globus Medical (GMED) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Globus Medical (GMED) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Globus Medical reported EPS of $1.23, above the $1.20 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +13.60%
    Streak
    6 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.31
    Range$1.21 - $1.39
    17 analysts
    Revenue Consensus
    $792.53M
    Range$748.43M - $823.73M
    17 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$1.19
    Range$1.09 - $1.28
    10 analysts
    EPS Revisions
    2
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$1.21-2.1%
    60d ago$1.22-2.6%
    30d ago$1.22-2.6%
    7d ago$1.22-2.4%
    Current$1.19
    Revenue Consensus
    $768.48M
    Range$725.35M - $795.24M
    8 analysts

    Next Report

    GMED has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.3% above the $1.28 reported for the quarter ended Dec 31, 2025.

    GMED Earnings Call

    The latest GMED earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, GMED beat 28, missed 8 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $763.72M, down 0.7% from $769.05M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.23$1.20$1.13 - $1.26+2.50%Beat+4.2%139 up, 0 downNov 5, 2026$763.72M
    Jun 30, 2026$1.34$1.12$1.05 - $1.14+19.64%Beat+55.8%1512 up, 1 downAug 6, 2026$789.61M
    Mar 31, 2026$1.12$0.92$0.80 - $1.06+21.74%Beat+64.7%136 up, 5 downMay 7, 2026$759.85M
    Dec 31, 2025$1.28$1.15$1.06 - $1.26+10.96%Beat+52.4%137 up, 0 downFeb 24, 2026$826.42M
    Sep 30, 2025$1.18$0.78$0.61 - $0.82+51.28%Beat+42.2%143 up, 9 downNov 6, 2025$769.05M
    Jun 30, 2025$0.86$0.76$0.72 - $0.82+13.16%Beat+14.7%133 up, 5 downAug 7, 2025$745.34M
    Mar 31, 2025$0.68$0.75$0.68 - $0.81-9.33%Miss-5.6%150 up, 7 downMay 8, 2025$598.12M
    Dec 31, 2024$0.84$0.75$0.65 - $0.87+12.21%Beat+40.0%142 up, 0 downFeb 20, 2025$657.29M
    Sep 30, 2024$0.83$0.65$0.59 - $0.68+27.69%Beat+45.6%150 up, 0 downNov 5, 2024$625.71M
    Jun 30, 2024$0.75$0.68$0.64 - $0.73+10.29%Beat+19.0%150 up, 0 downAug 6, 2024$629.69M
    Mar 31, 2024$0.72$0.57$0.49 - $0.62+26.32%Beat+35.8%151 up, 0 downMay 7, 2024$606.67M
    Dec 31, 2023$0.60$0.61$0.57 - $0.97-1.64%Miss+1.7%151 up, 0 downFeb 20, 2024$616.53M
    Sep 30, 2023$0.57$0.57$0.51 - $0.580.00%In line+14.0%131 up, 1 downNov 7, 2023$383.64M
    Jun 30, 2023$0.63$0.59$0.57 - $0.67+6.78%Beat+12.5%132 up, 0 downAug 3, 2023$291.62M
    Mar 31, 2023$0.53$0.51$0.49 - $0.53+3.92%Beat+26.2%150 up, 0 downMay 4, 2023$276.69M
    Dec 31, 2022$0.59$0.56$0.55 - $0.62+5.36%Beat+20.4%150 up, 1 downFeb 21, 2023$274.50M
    Sep 30, 2022$0.50$0.52$0.50 - $0.54-3.85%Miss0.0%150 up, 1 downNov 8, 2022$254.15M
    Jun 30, 2022$0.56$0.53$0.51 - $0.57+5.66%Beat0.0%130 up, 0 downAug 4, 2022$263.65M
    Mar 31, 2022$0.42$0.47$0.45 - $0.51-10.64%Miss-14.3%141 up, 1 downMay 10, 2022$230.55M
    Dec 31, 2021$0.49$0.47$0.45 - $0.52+4.26%Beat-15.5%14N/AFeb 17, 2022$250.02M
    Sep 30, 2021$0.50$0.45$0.44 - $0.48+11.11%Beat+2.0%150 up, 0 downNov 4, 2021$229.72M
    Jun 30, 2021$0.56$0.44$0.39 - $0.49+27.27%Beat+700.0%16N/AAug 4, 2021$251.02M
    Mar 31, 2021$0.49$0.37$0.30 - $0.42+32.43%Beat+69.0%16N/AMay 4, 2021$227.34M
    Dec 31, 2020$0.58$0.51$0.47 - $0.58+13.73%Beat+18.4%16N/AFeb 17, 2021$233.44M
    Sep 30, 2020$0.49$0.31$0.20 - $0.37+58.06%Beat+14.0%14N/AOct 28, 2020$216.10M
    Jun 30, 2020$0.07-$0.11-$0.25 - $0.09+163.64%Beat-82.9%12N/AAug 5, 2020$148.92M
    Mar 31, 2020$0.29$0.38$0.29 - $0.43-23.68%Miss-19.4%11N/AMay 7, 2020$190.58M
    Dec 31, 2019$0.49$0.52$0.50 - $0.54-5.77%Miss+14.0%14N/AFeb 20, 2020$211.67M
    Sep 30, 2019$0.43$0.42$0.39 - $0.44+2.38%Beat+10.3%13N/ANov 6, 2019$196.22M
    Jun 30, 2019$0.41$0.41$0.38 - $0.420.00%In line-6.8%13N/AAug 1, 2019$194.54M
    Mar 31, 2019$0.36$0.41$0.40 - $0.44-12.20%Miss-12.2%13N/AMay 2, 2019$182.95M
    Dec 31, 2018$0.43$0.39$0.38 - $0.43+10.26%Beat+13.2%13N/AFeb 21, 2019$195.94M
    Sep 30, 2018$0.39$0.32$0.31 - $0.34+21.88%Beat+30.0%11N/ANov 8, 2018$169.24M
    Jun 30, 2018$0.44$0.35$0.30 - $0.36+25.71%Beat+37.5%11N/AAug 1, 2018$173.38M
    Mar 31, 2018$0.41$0.36$0.35 - $0.37+13.89%Beat+36.7%10N/AMay 2, 2018$174.41M
    Dec 31, 2017$0.38$0.35$0.33 - $0.36+8.57%Beat+22.6%12N/AFeb 21, 2018$176.03M
    Sep 30, 2017$0.30$0.30$0.28 - $0.310.00%In line+3.4%13N/ANov 8, 2017$151.74M
    Jun 30, 2017$0.32$0.30$0.28 - $0.31+6.67%Beat+10.3%12N/AAug 2, 2017$152.39M
    Mar 31, 2017$0.30$0.30N/A0.00%In line0.0%N/AN/AMay 3, 2017$155.81M
    Dec 31, 2016$0.31$0.33N/A-6.06%Miss-3.1%N/AN/AFeb 27, 2017$151.59M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $4.00, up 27.4% from the year before. It was $1.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$4.00+27.4%
    Dec 31, 2024$3.14+34.8%
    Dec 31, 2023$2.33+12.6%
    Dec 31, 2022$2.07N/A
    Dec 31, 2021$2.04+42.7%
    Dec 31, 2020$1.43-15.4%
    Dec 31, 2019$1.69N/A
    Dec 31, 2018$1.67+28.5%
    Dec 31, 2017$1.30+9.2%
    Dec 31, 2016$1.19N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,04414
    2026Q2Jun 30, 20267,13113
    2026Q1Mar 31, 20268,66615
    2025Q4Dec 31, 20259,57216
    2025Q3Sep 30, 20258,37313
    2025Q2Jun 30, 202510,02914
    2025Q1Mar 31, 20256,06613
    2024Q4Dec 31, 202410,07715

    2026Q3 Earnings Call

    Opening remarks

    Shagun Singh Senior Vice President of Strategy and Investor Relations Thank you for being with us today. Joining today's call from Globus Medical will be Keith Pfeil, President and Chief Executive Officer, and Kyle Kline, Chief Financial Officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com. As a reminder, our discussion may include forward-looking statements, and such statements are subject to risks and uncertainties that could cause actual and anticipated results to differ materially. Please refer to the cautionary language in the earnings release and in the company's filings with the Securities and Exchange Commission for additional information. Except as may be required by applicable law, we do not undertake to update any forward-looking statements. Additionally, we will be discussing certain non-GAAP financial measures on this conference call. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. They should not, however, be considered replacements for, or be read other than together with, the most directly comparable GAAP financial measures. Additional information regarding these non-GAAP financial measures, as well as reconciliations for such non-GAAP measures, is included in the earnings release and is available on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Keith Pfeil, our President and Chief Executive Officer.

    Keith Pfeil President and Chief Executive Officer Thanks, Shagun, and good afternoon, everyone. Before I discuss the quarter, I'd like to formally welcome Shagun Singh to Globus as our new Senior Vice President of Strategy and Investor Relations. Shagun brings more than 20 years of health care investment research experience with deep expertise in medical technology and the investment landscape. She will lead our Investor Relations function as we expand engagement with our shareholders. As our business has grown in size and complexity, we separated Investor Relations from Corporate Development so that each has dedicated leadership. Brian Kearns, who has led both functions for the past 12 years, will continue as Senior Vice President of Corporate Development. I want to thank Brian for the work he's done, building relationships with many of you on this call. With that, let's turn to our third quarter results and the longer-term outlook. Our third quarter results totaled $763.7 million, declining 0.7% on an as-reported basis and declining 0.5% on a constant currency basis, reflecting the continued impacts of our rightsizing of Nevro, the timing of delayed new product launches within U.S. Spine, and lower contributions from competitive recruiting. Base business revenue, excluding Nevro, was $690 million, growing 3% as reported, while Nevro was $73.7 million, declining 25.7% compared to the prior-year quarter.

    Frequently Asked Questions About GMED

    When is Globus Medical's next earnings date?

    Globus Medical's next earnings report is expected for Feb 22, 2027.

    Did GMED beat earnings estimates last quarter?

    Yes. Globus Medical reported EPS of $1.23 for the quarter ended Sep 30, 2026, above the $1.20 estimate, a 2.50% surprise.

    What EPS do analysts expect from GMED next quarter?

    The consensus EPS estimate for Globus Medical for the quarter ending Dec 31, 2026 is $1.31 from 17 analysts, with estimates from $1.21 to $1.39.

    How often does GMED beat earnings estimates?

    Globus Medical beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +15.27%.